Diabetic kidney disease affects a growing proportion of people with diabetes and remains the leading cause of end-stage renal ...

Diabetic kidney disease is a leading cause of kidney failure worldwide, yet current treatments often slow progression ...

An American Heart Association presidential advisory in 2023 introduced a new term: cardiovascular-kidney-metabolic syndrome.

With kidney disease on the rise worldwide, we asked the nation's top specialists to share the early signs of the condition.

Objectives Given the rapidly evolving therapeutic landscape for type 2 diabetes (T2D) and chronic kidney disease (CKD), this study aimed to characterise the clinical profiles and real-world outcomes ...

The FDA has authorized Mayo Clinic to offer mesenchymal stem cells as part of the Regenerative Nephrology Compassionate Use Program. This is an expanded access program.

The year saw the emergence of a new version of an old drug that proved beneficial in patients who have heart failure with ...

In 2026, Robert F. Kennedy Jr.'s health policy changes will start playing out on GLP-1s, dietary guidelines, and rural health ...

Many doctors agree with the Food and Drug Administration’s recent decision to remove the black box warnings on at least some ...

Neighborhood-level social determinants of health were associated with varying cancer risks and greater mortality among kidney ...

Dr Mark Kris breaks down the lazertinib-amivantamab data, noting that the combo shows benefit but fails to address key ...

Metabolic diseases, including but not limited to diabetes mellitus, metabolic-associated fatty liver disease, hyperlipidemia, hyperuricemia, and gout, are ...